(Q34034067)

30 July 2017

1 reference

title

The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs: a review of the literature (English)

1 reference

30 July 2017

0 references

Hawkins C

1

1 reference

PubMed ID

10989252

30 July 2017

Hanks GW

series ordinal

2

1 reference

30 July 2017

1 August 2000

1 reference

Journal of Pain and Symptom Management

30 July 2017

1 reference

30 July 2017

20

1 reference

30 July 2017

2

1 reference

30 July 2017

140-151

1 reference

Nonsteroidal anti-inflammatory drug-induced gastrointestinal injury

30 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Nonsteroidal anti-inflammatory drugs: gastropathy, deaths, and medical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Deriving dichotomous outcome measures from continuous data in randomised controlled trials of analgesics

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Treating acute pain in hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Use of nonsteroidal anti-inflammatory drugs in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Prevention of nonsteroidal anti-inflammatory drug-induced gastroduodenal ulcers: role of mucosal protective and gastric antisecretory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Emergency admissions for upper gastrointestinal disease and their relation to NSAID use.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

NSAIDs, Cox-2 inhibitors, and the gut

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Oxygen free radicals interact with indomethacin to cause gastrointestinal injury

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Separation of the impairment of haemostasis by aspirin from mucosal injury in the human stomach

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

The relative gastrointestinal toxicity of the nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Risk of upper gastrointestinal bleeding and perforation associated with Individual non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Prophylactic aspirin and risk of peptic ulcer bleeding

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Nonsteroidal anti-inflammatory drug-associated gastropathy: incidence and risk factor models

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Audit and use of NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

A guideline for the treatment and prevention of NSAID-induced ulcers. Members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Toxicity of NSAIDs in the stomach and duodenum

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Misoprostol in patients taking non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Sucralfate treatment of nonsteroidal anti-inflammatory drug-induced gastrointestinal symptoms and mucosal damage.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Cimetidine therapy in nonsteroidal anti-inflammatory drug gastropathy. Double-blind long-term evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatory drugs: controlled trial of ranitidine

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Effect of ranitidine on gastroduodenal mucosal damage induced by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid Suppression Trial: Ranitidine versus Omeprazole for NSAID-associated Ulcer Treatment (ASTRONAUT) Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Famotidine for the prevention of gastric and duodenal ulcers caused by nonsteroidal antiinflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

High-dose ranitidine for the prevention of recurrent peptic ulcer disease in rheumatoid arthritis patients taking NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Prevention of NSAID-induced gastric ulcer with misoprostol: multicentre, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Perspective on the gastric antisecretory effects of misoprostol in man

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Duodenal and gastric ulcer prevention with misoprostol in arthritis patients taking NSAIDs. Misoprostol Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Misoprostol dosage in the prevention of nonsteroidal anti-inflammatory drug-induced gastric and duodenal ulcers: a comparison of three regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

The gastroduodenal safety and efficacy of the fixed combination of diclofenac and misoprostol in the treatment of osteoarthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

A double-blind comparison of the gastroduodenal safety and efficacy of diclofenac and a fixed dose combination of diclofenac and misoprostol in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Famotidine for healing and maintenance in nonsteroidal anti-inflammatory drug-associated gastroduodenal ulceration.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Ranitidine in the treatment of non-steroidal anti-inflammatory drug associated gastric and duodenal ulcers

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Nonsteroidal Anti-Inflammatory Drugs and Gastrointestinal Disease: Pathophysiology, Treatment and Prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Economic evaluation of gastric ulcer prophylaxis in patients with arthritis receiving non-steroidal anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Cost-effectiveness of misoprostol in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Inducible isoforms of cyclooxygenase and nitric-oxide synthase in inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

NSAIDs, Cox-2 inhibitors, and the gut

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

A six-month double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Improvement in gastrointestinal tolerability of the selective cyclooxygenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large-scale Evaluation of COX-inhibiting Therapies (SELECT) trial in osteoarthriti

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

1 reference

7 January 2021

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Analgesic efficacy of the cyclooxygenase-2-specific inhibitor rofecoxib in post-dental surgery pain: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Impaired vasodilatory responses in the gastric microcirculation of anesthetized rats with secondary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Novel nonsteroidal anti-inflammatory drug derivatives with markedly reduced ulcerogenic properties in the rat

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

A diclofenac derivative without ulcerogenic properties

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Anti-inflammatory potency and gastrointestinal toxicity of a new compound, nitronaproxen.

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

Many NSAID users who bleed don't know when to stop

1 reference

https://api.crossref.org/works/10.1016%2FS0885-3924%2800%2900175-5

7 January 2021

10.1016/S0885-3924(00)00175-5

Identifiers

DOI

1 reference

30 July 2017

1 reference

PubMed ID

10989252